The immune system has a remarkable capacity to maintain a state of equilibrium even as it responds to a diverse array of foreign proteins and despite its contact exposure to self-antigens. Apoptosis is one of the mechanisms aimed at preserving the homeostasis after the completion of an immune response, thus returning the immune system to a basal state and warranting the elimination of autoagressive cells in both central and peripheral lymphoid organs. Targeted deletions in critical genes involved in the apoptotic death machinery together with natural spontaneous mutations have clearly shown the importance of apoptosis in the regulation of the immune response. This complex scenario of stimulatory and inhibitory genes has been enriched with the finding that galectin-1, a 14.5 kDa [3-galactoside-binding protein, is able to induce apoptosis of immature cortical thymocytes and mature T cells by cross-linking cell surface glycoconjugates. Galectin-1 is present not only in central and peripheral lymphoid organs, but also at sites of immune privilege. In the present article we will discuss the implications of galectin-1-induced apoptosis in T-cell physiopathology in an attempt to validate its therapeutic potential in autoimmune and inflammatory diseases.
INTRODUCTION
Death, along with growth and differentiation, is a critical part of the life cycle of the cell. Homeostasis control of cell number is thought to be the result of the dynamic balance between cell proliferation and cell death. It is only in the past ten years, that the attention has been focused on the physiological occurrence of cell death and its role in the homeostasis.
Apoptosis or programmed cell death, is a phenomenon that plays a crucial role in a myriad of physiological and pathological processes. This review will briefly cover some relevant aspects of programmed cell death in the immune system in an attempt to provide valuable information about new molecules responsible for triggering death signals, such as galectin-1. The implications of this protein will be discussed in the context of T cell physiology and the regulation of central and peripheral tolerance. Finally, novel and intriguing findings will also be discussed implicating the use of this carbohydrate-binding protein in the treatment of autoimmune and inflammatory diseases.
APOPTOSIS: A PHYSIOLOGICAL MECHANISM OF HOMEOSTASIS AND SELF-TOLERANCE IN THE IMMUNE SYSTEM
Physiological cell death by activation of intrinsic cell suicide program, provides an efficient and critical control point for eliminating unwanted cells. This type of regulation allows the elimination of cells that have been produced in excess, have developed improperly, or have sustained genetic damage (Schwartzman and Cidlowski, 1993, Thompson, 1995) . As to the initiation of the death program, the decision of a cell to undergo apoptosis can be influenced by a wide variety of extrinsic and intrinsic regulatory stimuli (Thompson, 1995) . On the other hand, the effector stage takes place after triggering a number of evolutionarilly conserved genes that regulate a final common cell death pathway, that is preserved from invertebrates to humans (Vaux el al., 1994; Raft, 1992) .
Programmed cell death is an important physiological process acting both during development and homeostasis. Aberrations in this process are implicated in a broad range of diseases. While loss of apoptotic response can lead to cancer or autoimmune diseases, an increased apoptotic rate is implicated in neurodegenerative diseases, brain ischaemia and myocardial infarction. In this context, the immune system offers an excellent scenario for the discussion of the relevance of apoptosis in the development and maintenance of homeostasis. Immunologists have focussed largely on defining the stimuli that induce growth, differentiation and effector functions of lymphocytes and over the last two decades, the essential feature of lymphocyte activation and immune responses have been defined in considerable detail. Less is known, however, about the mechanisms that terminate immune responses. Mechanisms such as apoptosis are important after a productive immune response to a foreign antigen, when the immune system is returned to a state of rest (Surh and Sprent, 1994) . A high percentage of the thymocytes generated daily die within the thymus. Hence, massive cell death is a crucial part of T-cell development, as reflected by the fact that each new T cell undergoes for self-MHC restriction and self-tolerance. Thymocytes that success fully pass through positive and negative selections down-regulated the expression of either CD4 or CD8 and differentiate into functional single-positive cells and go out as mature T cells to the periphery.
Apoptosis in DP thymocytes is also triggered by glucocorticoids (Surh and Sprent, 1994) . The induction of cell death in thymocytes by glucocorticoids was one of the first systems studied by Wyllie (1980) and Cohen et al. (1992) . This work provides an early model of cell death by a specific signaling molecule and was fundamental to the development of the concept of active cell death as a cellular response rather than a passive act of overwhelming cell damage. Thymocytes, in addition to T-cells lines, are highly sensitive to apoptosis induced by exposure to endogenous glucocorticoids (Sprent et al., 1988) in an active process, requiring de novo gene expression (Wyllie, 1980) . In this sense, Ashwell and colleagues performed in vivo experiments Vacchio et al., 1994 , King et al., 1995 (Tanaka et al., 1995; Suda et al., 1995) . This molecule has been shown to play a role in the maintenance of peripheral T-and B-cell homeostasis. Noteworthy, in some circumstances FasL can be proteolitically cleaved from the membrane by a metalloproteinase, occuring in a soluble form that can act as a cytotoxic effector molecule or an inhibitor of apoptosis (Strand and Galle, 1998) .
The Fas-mediated apoptotic cascade is initiated by the direct association of the death receptor Fas with the adapter molecule FADD (Fas-associated protein with death domain) and the effector protease FLICE (FADD homologous ICE/ CED-3-1ike prtease, FADD-like ICE), a member of the ICE/Ced-3/caspase family (Henkart, 1996) (Russel et al., 1993; (Bruner et al., 1995; Dhein et al., 1995; Ju et al., 1995) . In the recent years, much work has focused on the molecular mechanisms by which these molecules regulate apoptosis specially the relationship of Fas-FasL interaction with members of the Bcl-2 family in the context of peripheral immune tolerance . van Genetic defects that predispose to autoimmunity are providing valuable information about the mechanisms responsible for terminating T-cell responses to self-antigens. In this sense, the importance of Fas/ FasL interaction in peripheral tolerance, has been highlighted by the MRL-lpr/lpr or C3H-gld/gld mice strains which carry spontaneous mutations in Fas and FasL genes respectively. These mice exhibit multiple autoimmune systemic disorders characterized by the presence of autoantibodies, hypergammaglobulinemia and immune complex nephritis, all features of a lupus-like syndrome . Nagata and colleagues (Adachi et al., 1995) created a Fas-/-mice by targeted deletion of the Fas gene. These mice displayed enhanced and accelerated lymphoproliferation in comparison to lpr/lpr mice (Adachi et al., 1995) .
Recently, a human syndrome of autoimmunity associated lymphadenophathy has been described, carrying various inherited abnormalities in Fas-mediated killing. These abnormalities include the inheritance of two mutant Fas alleles and unknown signalling defects (Fisher et al., 1995; Rieux-Laucat et al., 1995) . It is likely that other alteration in Fas or downstream signalling intermediates will be identified as cause of autoimmune syndromes. Recently, an inhereted human caspase 10 mutation has been described showing defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome (type II) (Wang et al., 1999) .
The elucidation of the mechanisms involved in T cell survival in vivo will lead to rational approaches for controlling autorreactivity, while enhancing immunological memory. (Streilin, 1993) .
FasL has been also reported to be constitutively expressed in two immunologically privileged tissues, such as the eye and the testis. Griffith et al. (1995) showed that the constitutive expression of FasL on parenchymal cells within the anterior chamber of the eyes can maintain the integrity of this immune-privileged site. It can be reported that Fas+ lymphoma cells can be induced to undergo apoptosis when exposed in vitro to explants of cornea and iris-ciliary body from eyes of normal mice, but not when exposed to eyes of gld mice, which do not express FasL. Interestingly, FasL has been found to be expressed in Sertoli cells of the testis (Bellgrau, 1995) .
Taken together, these finding unequivocally suggest that FasL plays a crucial role by avoiding the damage inflicted by activated T cells to these tissues. The expression of high levels of FasL represents a defensive mechanism to prevent damage caused by inflammation through an induction of apoptosis of activated cells expressing elevated levels of Fas antigen (Osborne, 1996) .
Recent (Rabinovich, 1999 (Ozeki et al., 1995) and laminin (Zhou and Cummings, 1993) and cell surface glycoproteins such as CD45 and CD43 (Baum et al., 1995a , Perillo et al., 1995 through deciphering specific glycocodes (Kasai and Hirabayashi, 1996) .
By virtue of this specific recognition, this evolutionarily conserved family of animal lectins have been implicated in a variety of functions that include cell growth regulation (Sandford and Harris-Hooker, 1990; Wells and Mallucci, 1991) , cell adhesion (Cooper et al., 1991; Zhou and Cummings, 1993; Rabinovich et 
GALECTIN-I: EXPRESSION WITHIN THE IMMUNE SYSTEM AND IMPLICATIONS IN T-CELL PHYSIOLOGY Participation of Galectin-I as a Gear of the Central and Peripheral Cell Death Machinery
Galectin-1 has been shown to be expressed in sites where T-cell apoptosis takes places including the thymus (Baum et al., 1995a) , spleen (Rabinovich et al., 1996) and lymph nodes (Baum, et al., 1995b) . It has been particularly found in thymic epithelial cells (Baum et al., 1995a) , activated macrophages (Rabinovich, et al., 1998) and effector T cells (Blaser, et al., 1998) (Figure 1 ). The first evidence suggesting that galectin-1 could be involved in central immune tolerance was first suggested by Goldstone and Lavin (1991) , who reported an increase in the levels of galectin-1 mRNA during apoptosis induced by glucocorticoids. As clearly stated, the interplay between thymic steroids and TCR signals modulate cell death within the thymus (Wyllie, 1980) . It is well known that thymocyte maturation also requires the participation thymic epithelial cells and extracellular matrix components (Anderson et al., 1994; Anderson et al., 1996) (Adams and Hamilton, 1984; Adams et al. 1996) . Moreover, they are also key immunoregulatory cells able to turn off an established immune response (Aliprantis et al., 1996) . We determined that by using current techniques to evaluate apoptosis, such as DNA fragmentation, TUNEL assay and transmission electron microscopy that galectin-1 produced by activated macrophages is able to induce apoptosis of mature T cells in a carbohydrate-dependent manner (Rabinovich et al., 1998) . The results were comparatively stronger to those found in an heterologous system using CLL-I, the 16 kDa chicken isolectin (Rabinovich et al., 1997).
RMGal protein was found to be secreted only when macrophages were activated with potent biochemical agents and pro-inflammatory cytokines (Rabinovich et al., 1999c ).
Galectin-1 Expression in Immune Privileged Sites" a Novel Mechanism of Protection?
Galectin-1 is also present in sites of immune privilege, such as placenta (Hirabayashi and Kasai, 1988; Iglesias et al., 1998a) , cornea (Ogden et al., 1998) and prostate (Allen et al., 1991; Hirabayashi and Kasai, 1993) . The presence of this protein in these vulnerable sites might contribute to mantain a state of tolerance by inducing apoptosis of inflammatory and activated T cells that could provoke injury, autoimmune damage or infection. Accordingly, galectin-1 could also be proposed as an alternative regulatory signal to regulate immune privilege. Expression of this protein in first term gestation placenta would prevent inflammatory T cells from harming the fetus (Iglesias et al., 1998a (1995) showed that the T lymphoblastoid cell line MOLT-4 that was unsensitive to FasL-induced apoptosis, was susceptible to galectin-1. In contrast, the T lymphoblastoid cell line CEM, which was sensitive to FasL was resistant to galectin-l-induced apoptosis. These data strongly suggest that galectin-l-induced apoptosis are clearly distinct from those triggered by Fas engagement.
About the apoptotic signal trigger by cross-linking the T-cell receptor complex, experiments performed whit galectin-1 and T lymphoblastoid cell line that not express CD3, demonstrate that the lectin is capable to activated the death cell program (Pace and Baum, 1997) . These results suggest that the mechanism by which galectin-1 can induced apoptosis appears to be distinct from T cell receptor trigger apoptosis.
Death vs proliferation: Galectin-1 vs Galectin-3
While galectin-1 has been shown to trigger T cell apoptosis (Perillo et a1.,1995; Rabinovich et al., 1998; Iglesias et al., 1998a) , galectin-3 has been shown to stimulate proliferation (Yang et al., 1996; Iglesias et al., 1998b; Inohara et al., 1998) . Similarly to members of the Bcl-2 family, galectins-1 and -3 belong to an additional family of proteins with high sequence homologies but opposite effects on cell survival. The balance between the competing activities of pro-apoptotic proteins such as Bax, Bad and Bak and on the other hand anti-apoptotic proteins such as Bcl-2 and Bcl-xL, determines cell fate (Adams and Cory, 1998) . Proteins most similar to Bcl-2 promote cell survival by inhibiti,ng adapters needed for activation of the proteases (caspases) that dismantle the cell, while more distant relatives instead promote apoptosis apparently through mechanisms that include displacing the adapters from the pro-survival proteins. In this sense, the family of Bcl-2 related proteins constitute one of the most relevant apoptotic regulatory gene products acting at the effector stage of apoptosis (Kr6emmer, 1997) . Hence, it seems meaningful that the interplay between galectins-1 and-3 could also represent an alternative pathway in the normal control of cell homeostasis. To support this hypothesis a striking homology has been found between galectin-3 and Bcl-2 particularly localized in the NWGR domain (Yang, 1996; Akahani et al., 1997) .
Galectin-1 in T cell Adhesion to Extracellular

Matrix
Despite the lack of a secretion signal sequence, galectin-1 is secreted into the extracellular millieu, where it recognizes poly-N-acetyl-lactosamine chains on major ECM components, such as laminin (Zho and Cummings, 1993) and fibronectin (Ozeki et al., 1995 (Zhou and Cummings, 1993) . (Cohen, 1995) . The rational answer for harmful activation is to find a way to deactivate the pathogenic lymphocytes. As aforementioned, observations in murine models of systemic autoimmunity and in Canale-Smith syndrome suggest that regula-tion of lymphocyte apoptosis is crucial to the maintenance of peripheral tolerance Fisher et al., 1995) . In this context, one should expect that knock out mice for galectin-1 would evidence autoimmune manifestations, such as lupus-like disorders or arthritis, as observed for spontaneous mutations in Fas and FasL in lpr/lpr or gld/gld mice respectively. However, no important phenotypic changes could be detected in null-mutant mice as regards galectin-1 gene (Poirrier and Robertson, 1993 ). An exhaustive examination of the immunological system is imperative in these genetically modified mice not only at the central level but also at the periphery to search for potentially harmfull autoaggressive clones and signs of disregulated apoptosis.
GALECTIN-1 IN T-CELL IMMUNOPATHOLOGY
Implications of galectin-1 in central and peripheral immune tolerance prompted us to investigate its therapeutic potential in collagen-type II-induced arthritis (CIA) in DBA/1 mice, an experimental model of rheumatoid arthritis (Durie et al., 1994 
